As it stands, Epitalons pharmacological profile is promising but incomplete, raising key questions about long-term safety, optimal dosing, and how to harness its effects in a reliable, standardized way
GHK-Cu is a small, positively charged molecule
The Endocrine Society's 2020 position statement on peptide therapeutics emphasizes that "the absence of Phase I dose-escalation data for novel peptides like BPC-157 means that any dose recommendation is extrapolated, not validated, and clinicians should err on the side of the lowest effective dose" 19
The results were remarkable, and other obesity researchers dubbed it agame-changer
For the scenario of "Currently Available Treatment," research data suggests Tirzepatide may be more relevant